PharmaResearch Co., Ltd. (214450.KQ)
ValueMarkers Composite Index
72% below intrinsic value ($732)
PharmaResearch Co., Ltd. (214450.KQ) — VMCI valuation read
PharmaResearch Co., Ltd. sits at VMCI 65/100, with the Healthcare sector median at 50. That 15-point spread is the first thing to note on 214450.KQ: it tells the reader the composite is favorable before any single ratio is examined, and the mid-cap tier sets the comparison set.
Form 4 disclosures on 214450.KQ are blank for the trailing 30 days. With the insider channel offline, the EV/EBITDA delta, free-cash-flow trajectory, and the next earnings print do the talking.
**Investor frame.** The Value read on 214450.KQ: 214450.KQ trades at 20.0x earnings, 11% above the Healthcare median of 18.0x, with EV/EBITDA at 13.0x against 12.0x. The Quality read: ROIC of 8.0% trails the Healthcare median (10.0%) by 2.0pp. The Risk read: net debt to EBITDA of 0.9x leaves covenant headroom, anchoring the bear scenario on a measurable balance-sheet metric.
214450.KQ rose 0.8% over the trailing 7 days, with a -15.4% read on a 30-day basis.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.